A new randomised controlled trial published in Frontiers in Nutrition in January 2026 has given every Magtein supplier India – and every supplement brand sourcing from one – a significantly stronger scientific foundation for cognitive health claims.
The study, authored by Lopresti and Smith at Clinical Research Australia and Murdoch University, enrolled 100 adults aged 18 to 45 and supplemented them with 2g/day of our patented and clinically studied ingredient Magtein® (Magnesium L-Threonate) for six weeks. The findings: measurable improvements in overall cognitive performance, cognitive age, working memory, episodic memory, reaction time, heart rate variability, and subjective sleep quality.
For Indian supplement brands working with a Magtein supplier India, this study changes the claims conversation – and the consumer segments it is appropriate to target.
What the 2026 Lopresti and Smith Study Found
Study Design – Why the Population Matters
Previous published Magtein® research focused primarily on older adults or animal models. The Lopresti and Smith (2026) trial specifically studied adults aged 18 to 45 with self-reported dissatisfied sleep – the first major RCT to validate Magtein® benefits in a young adult population.
The trial used the NIH Toolbox Cognition Battery – a standardised, validated assessment used in academic and clinical research globally. This gives the outcomes objective credibility beyond self-reported survey data, and provides a framework that supplement brands can reference directly in evidence-based marketing.
Cognitive Performance Outcomes from the Trial
The Magtein® group showed statistically significant improvement in the NIH Total Cognition Composite score (p = 0.043) compared to placebo. Larger treatment effects were documented specifically on working memory and episodic memory – the cognitive domains most impacted by digital overload and sleep disruption.
| Outcome Domain | Result vs. Placebo |
| Overall cognition (NIH Composite) | Significantly improved (p = 0.043) |
| Working memory | Larger treatment effect documented |
| Episodic memory | Larger treatment effect documented |
| Reaction time | Improved in Magtein® group |
| Heart rate variability (HRV) | Improved – objective stress resilience marker |
| Subjective sleep quality | Improved in dissatisfied-sleep population |
The Sleep-Cognition Dual Benefit – A New Formulation Angle for Indian Brands
What ‘Self-Reported Dissatisfied Sleep’ Maps to in India
The study enrolled participants with self-reported sleep dissatisfaction. In India’s urban professional context, this population is enormous. Research estimates that 93% of Indians are sleep deprived, with urban professionals aged 25-40 among the most affected – the same segment spending on cognitive health supplements.
The Lopresti and Smith (2026) trial found improvements in subjective sleep quality in this population alongside cognitive gains. A Magtein supplier India supplying Magtein® now sits at the intersection of two of the fastest-growing supplement categories in India: brain health and sleep wellness.
One Ingredient, Two Validated Claims
Most cognitive health supplement brands formulate separate SKUs for sleep and cognition. The 2026 trial data supports dual positioning of our patented and clinically studied ingredient Magtein® (Magnesium L-Threonate) within a single formulation, at 2g/day, for adults aged 18 to 45.
For formulators sourcing from a Magtein supplier India: this is a category-defining advantage. One clinical-backed ingredient. Two validated consumer claims. One SKU. Higher formulation value.
Why This Study Matters More for India Than Previous Magtein® Trials
India’s Cognitive Health Consumer Is 25-40, Not 65+
Previous Magtein® research positioned it primarily for cognitive aging in older adults. The Indian nutraceutical market has limited penetration in the 60+ segment for brain health supplements. The 18-45 age bracket is where India’s supplement growth is happening – driven by urban professionals, students, and Gen Z consumers managing high digital workloads.
The 2026 Lopresti and Smith study validates Magtein® specifically for this younger population – the exact segment every Indian supplement brand is formulating for. This makes the 2026 data more commercially relevant for India than any previous Magtein® clinical evidence.
Gen Z Screen Fatigue Meets Clinical Evidence
Gen Z in India spends an average of 7+ hours daily on screens. Screen overexposure is directly linked to working memory decline, attention fragmentation, and sleep disruption – the exact domains the Lopresti and Smith (2026) trial targeted and showed improvement on with our patented and clinically studied ingredient Magtein® (Magnesium L-Threonate).
Supplement brands citing a double-blind, placebo-controlled, peer-reviewed Frontiers in Nutrition trial – with a statistically significant cognition composite score (p = 0.043) – are in a fundamentally stronger marketing position than brands using generically sourced magnesium without clinical backing.
Magnesium L-Threonate vs. Other Magnesium Forms: What Formulators Need to Know
| Magnesium Form | Crosses Blood-Brain Barrier? | Primary Benefit | Brain Health Clinical Evidence |
| Magnesium L-Threonate (Magtein®) | Yes – L-threonate facilitates transport | Cognitive performance, sleep quality | 4+ published double-blind RCTs including Lopresti & Smith 2026 |
| Magnesium Glycinate | No significant brain penetration | Sleep, muscle relaxation | Systemic only – no brain-specific RCTs |
| Magnesium Citrate | No | Digestion, muscle function | Systemic only |
| Magnesium Oxide | No | Constipation, antacid use | Low bioavailability – limited clinical utility |
| Generic Mg L-Threonate | Not independently established | N/A | No published clinical trials |
2026 Lopresti & Smith Study: Quick Reference
| Study Parameter | Detail | Significance for India |
| Authors | Lopresti & Smith, Clinical Research Australia / Murdoch University | Independent, peer-reviewed institution – no industry bias |
| Publication | Frontiers in Nutrition, January 12, 2026 (doi: 10.3389/fnut.2025.1729164) | High-impact, open-access journal – citable for brand marketing |
| Population | 100 adults aged 18–45, self-reported dissatisfied sleep | Maps directly to India’s urban supplement consumer profile |
| Design | 6-week double-blind, placebo-controlled RCT, 2g/day Magtein® | Gold-standard trial design – supports regulatory-grade claims |
| Primary outcome | NIH Total Cognition Composite: significantly improved (p = 0.043) | Objective, validated instrument – not self-reported data alone |
| Secondary outcomes | Working memory, episodic memory, reaction time, HRV improved | Multi-domain cognitive benefit – supports broad claims |
| Sleep outcome | Subjective sleep quality improved in dissatisfied-sleep population | Enables dual-claim SKU: cognition + sleep in one ingredient |
What to Verify from a Credible Magtein Supplier India
A legitimate Magtein supplier India distributes the trademarked, patent-protected form – Magtein® by ThreoTech. Generic magnesium L-threonate exists in the market but carries no clinical trial backing. The distinction is critical for brand claims and regulatory defensibility.
Key verification points when sourcing from a Magtein supplier India:
- Certificate of Authenticity confirming Magtein® brand (not generic magnesium L-threonate)
- Third-party COA with magnesium L-threonate content verified by NABL-accredited laboratory
- Technical dossier referencing published clinical studies, including the 2026 Lopresti & Smith Frontiers in Nutrition trial
- FSSAI compliance documentation for the Indian market
- Regulatory guidance on permitted cognitive and sleep health claims under FSSAI guidelines
Key Takeaways
- The 2026 Lopresti & Smith Frontiers in Nutrition RCT is the first major trial validating Magtein® in adults aged 18-45 – India’s core supplement demographic
- Significant improvements documented in overall cognition (p = 0.043), working memory, episodic memory, reaction time, and HRV at 2g/day for 6 weeks
- Subjective sleep quality improvements were also documented – enabling dual-claim positioning (cognition + sleep) in a single formulation
- Generic magnesium L-threonate has no clinical backing – only Magtein® (ThreoTech) carries published RCT evidence
- A credible Magtein supplier India provides Certificate of Authenticity, third-party COA, and full regulatory documentation for the Indian market
Frequently Asked Questions
| FAQs: Magtein supplier India |
| 1. What did the 2026 Lopresti and Smith study on Magtein® find? Published in Frontiers in Nutrition (January 12, 2026; doi: 10.3389/fnut.2025.1729164), this double-blind RCT studied 100 adults aged 18-45 supplementing with 2g/day of our patented and clinically studied ingredient Magtein® (Magnesium L-Threonate) for 6 weeks. The Magtein® group showed significantly greater overall cognitive performance (NIH Total Cognition Composite, p=0.043), with larger effects on working memory, episodic memory, reaction time, heart rate variability, and subjective sleep quality vs. placebo. |
| 2. How does Magtein® cross the blood-brain barrier? The L-threonate chelate in Magtein® facilitates transport through the blood-brain barrier via glucose transporter mechanisms, enabling significant increases in brain magnesium concentrations. This mechanism is not shared by other magnesium forms – citrate, glycinate, or oxide. Brain magnesium elevation is what enables the cognitive performance benefits measured in clinical trials across all published Magtein® research. |
| 3. Can Magtein® support both sleep and cognitive health claims in a single formulation? Yes. The 2026 Lopresti and Smith trial specifically supports this dual positioning – participants showed improvements in both cognitive performance metrics and subjective sleep quality from the same 2g/day dose over 6 weeks. Indian supplement brands working with a credible Magtein supplier India can formulate a single SKU supporting both claims with published peer-reviewed clinical data. |
| 4. What is the clinical dose of Magtein® for cognitive benefits? The 2026 Lopresti and Smith trial used 2g per day of our patented and clinically studied ingredient Magtein® (Magnesium L-Threonate), delivering approximately 145mg of elemental magnesium. This aligns with dosing from previous Magtein® clinical trials. A credible Magtein supplier India will provide use-level guidance aligned with published clinical study protocols. |
| 5. Is generic magnesium L-threonate the same as Magtein®? No. Magtein® is a trademarked, patented form of magnesium L-threonate developed by ThreoTech, backed by 4+ published double-blind RCTs including the January 2026 Lopresti & Smith Frontiers in Nutrition study. Generic magnesium L-threonate is chemically similar but carries no clinical trial evidence. Brands making cognitive health claims should source only authenticated Magtein® from a verified Magtein supplier India. |
Sourcing our patented and clinically studied ingredient Magtein® (Magnesium L-Threonate) for your cognitive health or sleep supplement?
Avlaan Pharmaceutical is an authorised Magtein supplier India – with complete regulatory documentation, technical dossiers referencing the 2026 clinical study, and formulation guidance for Indian supplement brands.
Email: info@avlaanpharma.com | Phone: +91 9677 239 111 | Website:avlaanpharma.com